A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data

November 12, 2026 updated by: Novartis Pharmaceuticals

Characterising the Elevated Liver Enzymes in Ribociclib (Kisqali®) Treatment Among Patients With HR+ HER2- Advanced Breast Cancer Using a Machine Learning Approach With Real-world Data

The aim of this study is to assess key factors associated with response and non-response to the current established management algorithm for elevated liver enzymes (ELE) following ribociclib treatment in hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (aBC) patients in real world settings in the United States (US). The data for this study will be drawn from a US-based breast cancer specific electronic health record (EHR) database.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

8001

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Novartis Pharmaceuticals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Adult patients in the US with a diagnosis of HR+/HER2- aBC and evidence of ribociclib use.

Description

Inclusion criteria:

  1. Evidence of diagnosis of Stage IV breast cancer (aBC) as per American Joint Committee on Cancer (AJCC), 8th Edition during study period
  2. Aged 18 years or older at the index date
  3. Have at least one prescription for Ribociclib
  4. Have lab values available for alanine aminotransferase/aspartate aminotransferase (ALT/AST) at baseline, and up to 6 months post-baseline (at least one measurement at baseline and one measurement during follow up)

Exclusion criteria:

  1. Missing values for patient ID or age
  2. No available lab data for liver enzymes (ALT/AST) at either baseline or up to 6 months post-baseline

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Ribociclib Treatment Responders

Patients who undergo a management action (dose reduction or temporary suspension) and achieve recovery to ≤ baseline grade ALT/AST within 60 days without permanent treatment discontinuation or treatment switch.

Ribociclib Treatment Non-responders

Patients who undergo a management action (dose reduction or temporary suspension) but whose ALT/AST level does not recover to baseline grade within 60 days, experience a worsening grade, recurrence after rechallenge, permanent treatment discontinuation or switch to another systemic therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs
Time Frame: Baseline

Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, socioeconomic status (SES) index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of breast cancer (BC) diagnosis, type of BC, biomarker status, Eastern Cooperative Oncology (ECOG) performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities.

Baseline
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation
Time Frame: Baseline
Baseline
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up
Time Frame: Up to approximately 12 months
Up to approximately 12 months
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight
Time Frame: Baseline
Baseline
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Charlson Comorbidity Index (CCI)
Time Frame: Baseline

CCI is a weighted index that takes into account both the number and the seriousness of comorbid conditions. Each condition is assigned a weighted score, and the scores are summed to generate a total CCI score. Total scores range from 0 to 37, with higher scores reflecting a greater burden of disease and an increased risk of mortality.

Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs
Time Frame: Baseline

Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, SES index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of BC diagnosis, type of BC, biomarker status, ECOG performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities.

Baseline
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation
Time Frame: Baseline
Baseline
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up
Time Frame: Up to approximately 12 months
Up to approximately 12 months
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight
Time Frame: Baseline
Baseline
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, CCI
Time Frame: Baseline
Baseline
Among aBC Patients Who Experience a First ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients With Subsequent Episodes of ALT/AST Elevation
Time Frame: Up to approximately 12 months
Up to approximately 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 13, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CLEE011A2010

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.